Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MRK vs UNOV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MRK Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

MRK Overall Winner 6-Pillar Tally: MRK 6 – 0 UNOV Matrix Metrics: MRK 7 – 3 UNOV

As of Nov 16, 2026, Merck & Co., Inc. (MRK) is the stronger overall head-to-head candidate over Innovator U.S. Equity Ultra Buffer ETF - November (UNOV) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MRK carries a Unified Composite Score of 56.6/100 (HOLD) at $144.46 (16.1x Forward P/E, 35.2% operating margin), whereas UNOV carries 58.7/100 (HOLD) at $41.13 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While UNOV currently prints a higher short-term Unified Composite Score (58.7/100 HOLD vs. MRK 56.6/100 HOLD), MRK captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (35.2% vs. N/A operating margin) and revenue trajectory (+4.7% vs. N/A YoY).
  • Technical & Structure Timing Caution: MRK is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.0); meanwhile UNOV trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRK vs UNOV
MRK NYSE Head-to-Head Winner
Merck & Co., Inc.
Pharmaceutical Preparations
$144.46
-2.23% 1D
Market Cap $364.3B
TTM Revenue $67.4B
Forward P/E 16.1x
Beta / 30D Vol 0.20β · 32% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope 0.4%) with fading momentum, RSI 47
RSI-14: 47.0 · SMA20: $146.51 · SMA50: $146.02
UNOV Cboe BZX
Innovator U.S. Equity Ultra Buffer ETF - November
Pharmaceutical Preparations
$41.13
-0.95% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.46β · 11% Vol
Unified Composite Score
58.7 / 100 HOLD
Tech 48.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.3 · SMA20: $41.59 · SMA50: $41.48

6-Pillar Scorecard Institutional Category Breakdown (MRK 6 – 0 UNOV)

Columns: Metric · MRK · UNOV
1. Valuation Multiples MRK
Forward P/E 16.1x N/M
Trailing P/E 147.8x N/M
PEG Ratio 3.58x N/M
EV / Revenue 6.1x N/M
2. Growth & Scale MRK
Revenue Growth (YoY) +4.7% N/A
Earnings Growth (YoY) -12.0% N/A
TTM Revenue (USD) $67.4B N/A
Market Cap $364.3B N/A
3. Profitability & Quality MRK
Gross Margin 75.2% N/A
Operating Margin 35.2% N/A
Net Profit Margin 3.6% N/A
Return on Equity (ROE) 5.1% N/A
4. Balance Sheet & Cash Flow MRK
Cash Generation (TTM) $14.7B N/A
Cash Flow Margin 21.9% N/A
Net Cash / Leverage $44.2B Net Debt (1.20x D/E) N/A ROE
Dividend Yield 2.29% None (0.00%)
5. Options & Positioning MRK
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 42.6% (46th %ile) N/A (N/A)
Put/Call OI Skew 0.69x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat MRK
OpEx & R&D Intensity 40.0% of Rev ($27.0B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - General Operator Pharmaceutical Preparations Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRK (7) vs UNOV (3)
Institutional Metric MRK UNOV Criterion Row Edge
Market Capitalization
Scale
$364.3B N/A Larger Scale MRK
Trailing P/E Ratio
Valuation
147.8x N/M Lower Multiple MRK
Forward P/E Ratio
Valuation
16.1x N/M Lower Multiple MRK
Revenue Growth (YoY)
Growth
+4.7% N/A Higher Growth MRK
Operating Margin (TTM)
Profitability
35.2% N/A Higher Margin MRK
Net Profit Margin
Profitability
3.6% N/A Higher Margin MRK
Return on Equity (ROE)
Capital Efficiency
5.1% N/A Higher ROE MRK
52-Week Range Position
Momentum
81% ($91–$157) 84% ($37–$42) Stronger Trend UNOV
Beta / 30D Volatility
Risk Regime
0.20β · 32% Vol 0.46β · 11% Vol Lower Realized Risk UNOV
Unified Institutional Score
Composite Signal
56.6 / 100 (HOLD) 58.7 / 100 (HOLD) Higher Composite UNOV
Trailing 12M Revenue (USD)
Operating Scale
$67.4B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.58x PEG · 6.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$14.7B ($44.2B Net Debt (1.20x D/E)) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon UNOV +0.05 pp
MRK: -1.02% · UNOV: -0.97%
3M Horizon MRK +6.43 pp
MRK: +6.87% · UNOV: +0.44%
6M Horizon MRK +24.92 pp
MRK: +28.34% · UNOV: +3.42%
1Y Horizon MRK +45.92 pp
MRK: +55.45% · UNOV: +9.53%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MRK vs UNOV. Trailing 12-month operating profitability (MRK 35.2% vs UNOV N/A) and valuation multiples (MRK 16.1x vs UNOV N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MRK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$67.4B
Gross Margin75.2%
Op. Margin35.2%
ROE / Fwd P/E5.1% · 16.1x
UNOV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRK CONSOLIDATION
58d in phase · OBV DISTRIBUTION
Current IV 42.6%
IV Percentile 46th %ile
Put/Call OI Skew 0.69x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
UNOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRK Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $364.3B market capitalization and 35.2% operating margin.
OpEx & R&D Reinvestment 40.0% of Rev ($27.0B)
90D Engineering Disclosures 0 Published
UNOV Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MRK vs UNOV Key Questions & Quantitative Answers

As of Nov 16, 2026, Merck & Co., Inc. (MRK) is the stronger overall head-to-head candidate over Innovator U.S. Equity Ultra Buffer ETF - November (UNOV) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MRK carries a Unified Composite Score of 56.6/100 (HOLD) at $144.46 (16.1x Forward P/E, 35.2% operating margin), whereas UNOV carries 58.7/100 (HOLD) at $41.13 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While UNOV currently prints a higher short-term Unified Composite Score (58.7/100 HOLD vs. MRK 56.6/100 HOLD), MRK captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (35.2% vs. N/A operating margin) and revenue trajectory (+4.7% vs. N/A YoY). Technical & Structure Timing Caution: MRK is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.0); meanwhile UNOV trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MRK leads the Growth & Scale pillar: MRK posts +4.7% YoY revenue growth and -12.0% YoY earnings growth on $67.4B TTM revenue (75.2% gross margin, 35.2% operating margin), compared with UNOV at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, MRK generates $67.4B in USD-normalized revenue versus N/A for UNOV. In operating R&D and SG&A reinvestment, MRK deploys 40.0% of Rev ($27.0B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for UNOV.

MRK screens cheaper on headline valuation multiples. MRK trades at 16.1x Forward P/E, 147.8x Trailing P/E, 3.58x PEG, and 6.1x EV/Revenue (21.9% FCF margin), whereas UNOV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRK (5.1% ROE) versus UNOV (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, MRK carries 42.6% implied volatility (46th %ile, Balanced (25th–60th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.20β · 32% Vol realized risk). By comparison, UNOV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 11% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.